The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a huge mover today! About 618,364 shares traded hands. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 55.33% since April 22, 2016 and is uptrending. It has outperformed by 49.92% the S&P500.
The move comes after 6 months positive chart setup for the $60.37M company. It was reported on Nov, 25 by Barchart.com. We have $2.62 PT which if reached, will make NASDAQ:EBIO worth $3.62 million more.
Analysts await Eleven Biotherapeutics Inc (NASDAQ:EBIO) to report earnings on March, 23.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Saturday, August 15 by Leerink Swann. The rating was maintained by Citigroup on Wednesday, March 16 with “Neutral”. The rating was downgraded by Citigroup on Tuesday, January 19 to “Neutral”. The firm has “Market Perform” rating given on Tuesday, January 19 by Leerink Swann.
According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”
Insitutional Activity: The institutional sentiment increased to 2.29 in 2016 Q2. Its up 1.29, from 1 in 2016Q1. The ratio is positive, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.
Renaissance Ltd Liability Corp accumulated 118,500 shares or 0% of the stock. Geode Capital Management Ltd Company reported 46,637 shares or 0% of all its holdings. Fincl Bank Of Montreal Can reported 15,000 shares or 0% of all its holdings. Blackrock Fund Advsrs accumulated 0% or 1,624 shares. Goldman Sachs Gp last reported 13,343 shares in the company. Natl Bank Of Mellon, a New York-based fund reported 67,483 shares. Two Sigma Lc last reported 0.02% of its portfolio in the stock. Vanguard Inc reported 77,656 shares or 0% of all its holdings. Royal Commercial Bank Of Canada last reported 0% of its portfolio in the stock. The Illinois-based Gp One Trading Ltd Partnership has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). The New Jersey-based Kcg Holding Incorporated has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). The California-based Reilly Financial Advsr Limited Liability Corp has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Susquehanna Intll Grp Llp last reported 26,654 shares in the company. Natl Bank Of America Corporation De, a North Carolina-based fund reported 35 shares. Blackrock Institutional Tru Co Na has 0% invested in the company for 149,618 shares.
EBIO Company Profile
Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.